These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10854186)

  • 1. Patient immune response to tumors monitored using SCID mouse models.
    Bankert RB; Chen FA; Sugiyama Y; Egilmez N
    Immunol Invest; 2000 May; 29(2):171-6. PubMed ID: 10854186
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune monitoring in cancer immunotherapy.
    Romero P; Pittet MJ; Valmori D; Speiser DE; Cerundolo V; Liénard D; Lejeune F; Cerottini JC
    Ernst Schering Res Found Workshop; 2000; (30):75-97. PubMed ID: 10943317
    [No Abstract]   [Full Text] [Related]  

  • 3. [New era of tumor immunotherapy].
    Yoshitake Y; Nakatsura T; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
    [No Abstract]   [Full Text] [Related]  

  • 4. How much help does a vaccine-induced T-cell response need?
    Weber JS; Mulé JJ
    J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
    [No Abstract]   [Full Text] [Related]  

  • 5. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.
    Wang T; Wang D; Yu H; Feng B; Zhou F; Zhang H; Zhou L; Jiao S; Li Y
    Nat Commun; 2018 Apr; 9(1):1532. PubMed ID: 29670088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T lymphocytes: the future of cancer stem cell eradication?
    Saijo H; Hirohashi Y; Torigoe T; Kochin V; Takahashi H; Sato N
    Immunotherapy; 2013 Jun; 5(6):549-51. PubMed ID: 23725275
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.
    Kloke BP; Mahr A; Jabulowsky RA; Kutscher S; Rae R; Britten CM
    Cancer Immunol Immunother; 2015 Jul; 64(7):923-30. PubMed ID: 25548093
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant antibody fusion proteins for cancer immunotherapy.
    Reisfeld RA; Gillies SD
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
    [No Abstract]   [Full Text] [Related]  

  • 9. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines.
    Nakamura Y
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):778-9. PubMed ID: 22252581
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
    Nishida S; Sugiyama H
    Methods Mol Biol; 2016; 1467():221-32. PubMed ID: 27417973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
    Chouaib S
    Tunis Med; 2005 Dec; 83 Suppl 12():7-10. PubMed ID: 16430055
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.
    Huang CH; Peng S; He L; Tsai YC; Boyd DA; Hansen TH; Wu TC; Hung CF
    Gene Ther; 2005 Aug; 12(15):1180-6. PubMed ID: 15800656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.
    Chouaib S
    J Clin Invest; 2003 Mar; 111(5):595-7. PubMed ID: 12618511
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic Cancer Vaccine and Immune Checkpoint Inhibitor].
    Mimura K; Kono K
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):733-736. PubMed ID: 28912398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making the most of mucin: a novel target for tumor immunotherapy.
    Barratt-Boyes SM
    Cancer Immunol Immunother; 1996 Nov; 43(3):142-51. PubMed ID: 9001567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting p53 for adoptive T-cell immunotherapy.
    McCarty TM; Liu X; Sun JY; Peralta EA; Diamond DJ; Ellenhorn JD
    Cancer Res; 1998 Jun; 58(12):2601-5. PubMed ID: 9635585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy with MAGE antigens.
    Coulie PG
    Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.